Ligand Pharmaceuticals News
Ligand Pharmaceuticals Incorporated announced today that Ligand management is scheduled to present at the following upcoming investor conferences:
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals IncorporatedPR Newswire May 17
NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches ...
Ligand Pharmaceuticals (Nasdaq:LGND) has been upgraded by TheStreet Ratings from a sell to hold.
InPlay: Ligand Pharma partner Rib-X initiates Phase 3 trial of Captisol-enabled delafloxacin IV; co earned a $500K milestone paymentMay 14
Ligand Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcript
Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2013, and provided an operating forecast and program updat